Enovis (ENOV)
(Delayed Data from NYSE)
$43.75 USD
-0.62 (-1.40%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $43.74 -0.01 (-0.02%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth B Momentum B VGM
Enovis (ENOV) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$73.00 | $82.00 | $53.00 | 64.53% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Enovis comes to $73.00. The forecasts range from a low of $53.00 to a high of $82.00. The average price target represents an increase of 64.53% from the last closing price of $44.37.
Analyst Price Targets (10)
Broker Rating
Enovis currently has an average brokerage recommendation (ABR) of 1.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.42 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 8.33% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 8.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ENOV.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.42 | 1.42 | 1.42 | 1.27 | 1.27 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
3/15/2024 | Argus Research Corp. | John M Eade | Hold | Hold |
2/23/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Strong Buy | Strong Buy |
2/22/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
2/13/2024 | Stephens | George Sellers | Not Available | Strong Buy |
1/22/2024 | UBS | Danielle Antalffy | Not Available | Strong Buy |
1/3/2024 | William Blair | Brandon Vazquez | Not Available | Strong Buy |
12/20/2023 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
10/21/2023 | Roth Capital Partners | Jason Wittes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.42 |
ABR (Last week) | 1.42 |
# of Recs in ABR | 12 |
Average Target Price | $73.00 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | 0.61 |